FDA
-
-
-
-
-
-
-
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
-
-
-
-
-
-
-
Daré Bioscience CEO discusses pipeline and commercial shift
-
-
-
-
-
-
-
Daré Bioscience plans June 2026 launch of vaginal probiotic product
-
-
-
-
-
-
-
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
-
-
-
-
-
-
-
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Dare Bioscience (DARE)
-
-
-
-
-
-
-
Dare Bioscience receives $4 million grant installment for drug delivery
-
335,381 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


